Oral topotecan: Bioavailability and effect of food co-administration

British Journal of Cancer

Volumn 80, Issue 9, 1999, Pages 1380-1386

  Herben, V M M ^a   Rosing, H ^a   Ten Bokkel Huinink, W W ^a   Van Zomeren, D M ^a   Batchelor, D ^a   Doyle, E ^b   Beusenberg, F D ^c   Beijnen, J H ^a   Schellens, J H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SmithKline Beecham Farma BV   (Netherlands)

Author keywords

Bioavailability; Food; Oral; Topotecan

Indexed keywords

GELATIN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPID DIET; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; BIOAVAILABILITY; FOOD; MIDDLE AGED;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FOOD; HUMANS; MALE; MIDDLE AGED; TOPOTECAN;

EID: 0032589190     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690532     Document Type: Article

References (20)

1. Ajani JA, Welch SR, Raber MN, Fields WS and Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147-159
2. Burris HA III, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG and Von Hoff DD (1992) Activity of topotecan, a new topoisomerase 1 inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 84: 1816-1820
3. Creemers GJ, Gerrits CJH, Eckardt JR, Schellens, JHM, Burris HA, Planting AST, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J and Von Hoff DD (1997) Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15: 1087-1093
4. Committee for Proprietary Medicinal Products (1992) Note for Guidance: Investigation of Bioavailability and Bioequivalence (III/54/89 EN). CPMP: Brussels
5. Davies BE, Minthorn EA, Dennis M, Beijnen JH and Rosing H (1995) The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Eur J Cancer 31A: S28
6. Eckardt J, Burris H, Rizzo J, Fields S, Rodrigues G, De la Cruz P, Hodges S, Von Hoff and Kuhn J (1995) A phase I safety and bioavailability study of oral topotecan. Eur J Cancer 31A: S193
7. Gerrits CJH, Burris H, Schellens JHM, Planting AST, Van der Burg MEL, Rodrigues GI, Van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J and Von Hoff DD (1998) Five days of oral topotecan (Hycamtin®), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 7: 34
8. Herbert VMM, Ten Bokkel Huinink WW, Dubbelman AC, Mandjes IAM, Groot Y, Van Zomeren DM and Beijnen JH (1997) Phase I and pharmacologic study of sequential intravenous topotecan and oral etoposide. Br J Cancer 76: 1500-1508
9. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK and Kingsbury WD (1989) Modification of the hydroxy lactone ring of camplothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720
10. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Danks MK and Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403
11. Hsiang Y-H and Liu LF (1998) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
12. Hsiang Y-H, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R and Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49: 4385-4389
13. Marzo A and Balani LP (1995) Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneim-Forsch/Drug Res 45: 109-115
14. Pabst G and Jaeger H (1990) Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Cancer 38: 5-10
15. Pommier Y, Jaxel C, Kerrigan D and Kohn KW (1991) Structure activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex. In DNA Topoisomerase in Cancer, Potmesil M and Kohn KW (eds). pp. 121-132. Oxford University Press; New York
16. Rosing H, Doyle E, Davies BE and Beijnen JH (1995) High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chrom B 668: 107-111
17. Rosing H, Herben VMM, Gortel-van Zomeren DM, Hop E, Kettenes-van den Bosch JJ, Ten Bokel Huinink WW and Beijnen JH (1997) Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 39: 498-504
18. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, De Boer-Dennert M, McDonald M, Davies B and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73: 1268-1271
19. Supko JG, Plowman J, Dyker DJ and Zaharko DS (1992) Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33: 432
20. Underberg WJM, Goossen RMJ, Smith BR and Beijnen JH (1990) Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8: 681-683